Overactive Bladder Syndrome
7
Pipeline Programs
3
Companies
5
Clinical Trials
5
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
6
Early DiscoveryClinical DevelopmentMarket
On Market (5)
Approved therapies currently available
U
DARIFENACINApproved
darifenacin
Unknown Companyoral2017
U
DARIFENACIN HYDROBROMIDEApproved
darifenacin
Unknown Companyoral2017
U
SOLIFENACIN SUCCINATEApproved
solifenacin succinate
Unknown Companyoral2019
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstellasSolifenacin Succinate
NovartisDarifenacin
NovartisDarifenacin
NovartisDarifenacin
TakedaPropiverine
Clinical Trials (5)
Total enrollment: 1,679 patients across 5 trials
Validation of a Real-time Urodynamic Measure of Urinary Urgency
Start: Jan 2007Est. completion: Feb 200951 patients
Phase 4Completed
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
Start: Apr 2004Est. completion: Dec 2004445 patients
Phase 3Completed
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
Start: Apr 2002Est. completion: Jan 2005718 patients
Phase 3Completed
Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects
Start: Jun 2006Est. completion: Sep 200728 patients
Phase 1Completed
Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
Start: Nov 2010Est. completion: Dec 2011437 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space